Savient Pharmaceuticals (SVNT)
Savient Pharmaceuticals Market Cap: 51.98M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SVNT Market Cap Rankings
| Overall | 15th percentile | 3957 of 4665 |
| Sector | 19th percentile | 422 of 527 in Healthcare |
| Industry | 18th percentile | 133 of 164 in Biotechnology |
SVNT Market Cap Range, Past 5 Years
| Minimum | 51.98M | May 31 2012 |
| Maximum | 1.546B | Sep 2010 |
| Average | 728.55M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these SVNT related companies
SVNT News
Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
May 25, 2:16PM Street Insider
May 25, 2:16PM Street Insider
@AvantNoir I'll wait till $SVNT shows a little green 1st, then stop it at the low of the day before.
about 11 days ago by Urbane_Gorilla
about 11 days ago by Urbane_Gorilla
Unusual 11 Mid-Day Movers 05/17: (MEG) (GALE) (XG) Higher; (WFR) (SVNT) (DANG) Lower
May 17, 1:06PM Street Insider
May 17, 1:06PM Street Insider
Savient Pharmaceuticals Completes Financing and Debt Restructuring Transactions
May 09, 3:32PM Benzinga
May 09, 3:32PM Benzinga
Listen to $SVNT Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3jw2
about 23 days ago by earningscast
about 23 days ago by earningscast
Savient Pharmaceuticals Enters Into Definitive Financing and Debt Restructuring Agreements
May 08, 6:41AM Benzinga
May 08, 6:41AM Benzinga
Savient (SVNT) Shares Hit as BioCryst (BCRX) Gets FDA Guidance for Gout Treatment Approval
May 07, 12:32PM Street Insider
May 07, 12:32PM Street Insider
Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 03, 4:05PM PR Newswire
May 03, 4:05PM PR Newswire
Unusual 11 Mid-Day Movers 05/02: (SMSC) (CHRS) (WWWW) Higher; (END) (UBNT) (CEVA) Lower
May 02, 1:24PM Street Insider
May 02, 1:24PM Street Insider
Savient Pharma (SVNT) Shares Nosedive as Co. Served with Credit Derivative Action
May 01, 1:52PM Street Insider
May 01, 1:52PM Street Insider
@jimo66 You have some interesting plays. Like $CBOU the best. Curious as to y $SVNT is going higher.
about 38 days ago by schenek
about 38 days ago by schenek
$SVNT moving above the swing high. Now maybe the shorts will start covering.
about 42 days ago by Lonetree
about 42 days ago by Lonetree
Option Alert: Savient Pharmaceuticals January 2013 2.5 Call; Block Trade, 2,000 Contracts
Apr 11, 10:57AM Benzinga
Apr 11, 10:57AM Benzinga
Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
Apr 03, 4:05PM PR Newswire
Apr 03, 4:05PM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SVNT | 0.7243 | -0.03 | -4.53% | 51.98M |
| SVN | 9.68 | -0.04 | -0.41% | 482.84M |
| SVM | 6.20 | +0.14 | +2.31% | 1.034B |
| SVBI | 3.21 | +1.02 | +46.58% | 32.32M |
| SVA | 1.85 | +0.03 | +1.65% | 101.08M |
| SUTR | 0.85 | -0.07 | -7.62% | 34.30M |
| SUSS | 28.79 | -0.46 | -1.57% | 612.79M |
| STLY | 3.90 | -0.05 | -1.20% | 56.63M |
| STLD | 10.32 | -0.22 | -2.09% | 2.309B |
| STL | 9.10 | -0.01 | -0.11% | 281.37M |
